Insmed discontinued development of Brinsupri (brensocatib) for hidradenitis suppurativa (HS) after the Phase 2b CEDAR study showed no efficacy signal.1
In the CEDAR study, at 16 weeks, abscess and inflammatory nodule counts dropped 45.5% (10-mg dose) and 40.3% (40-mg dose), but placebo achieved 57.1% reduction; secondary endpoints also missed.1
Brinsupri, a DPP1 inhibitor approved in August 2025 for non-cystic fibrosis bronchiectasis, will focus on its primary lung indication after this HS setback.1
Analysts at William Blair and Guggenheim were unsurprised, citing prior failure in rhinosinusitis and lack of preclinical data for HS.1
Competitors like Incyte (povorcitinib), Novartis, and UCB (Bimzelx, FDA-approved November 2024 for HS) advance in the space.1
Sources:
1. https://www.biospace.com/drug-development/insmed-scraps-skin-plans-for-lung-disease-drug-as-competitors-make-headway